The outcome of meeting of Board of directors held on Wednesday, March 18, 2026 has been attached herewith.
Awaiting price reaction for this filing.
Dharti Proteins' board met on March 18, 2026 and approved the un-audited standalone financial results for the quarter and nine months ended December 31, 2025. The company reported total revenue of Rs. 0.44 lakhs for Q3 and Rs. 2.93 lakhs for the nine-month period, while posting a net loss of Rs. 34.22 lakhs for the quarter and Rs. 35.24 lakhs for nine months (compared to a loss of Rs. 2.82 lakhs in the prior year period). The auditor issued a qualified opinion, flagging concerns around MSMED compliance, going concern status, doubtful loans of Rs. 150.46 lakhs, and the company not paying listing fees. The company has been under Corporate Insolvency Resolution Process (CIRP), with NCLT having approved a resolution plan submitted by Mr. Jatinbhai Ramanbhai Patel, which will materially reduce existing public shareholding to 25,000 shares and allot new shares to financial creditors and the resolution applicant.
This is a high-risk, loss-making micro-cap stock under insolvency resolution. The approved resolution plan will drastically dilute existing public shareholders to just 25,000 shares, while the new promoter and financial creditors will receive the majority of equity. Investors should be cautious as the company has a negative net worth of Rs. 146.42 lakhs, no business operations, and multiple auditor qualifications.